MDGL Q2 2024 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M

Gross Profit

$14M95.7% margin

Operating Income

-$163M-1110.4% margin

Net Income

-$152M-1038.2% margin

EPS (Diluted)

$-7.10

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$135M

Free Cash Flow

-$140M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$243M

Stockholders' Equity

$857M

Cash & Equivalents

$495M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$0	—
Gross Profit	$14M	$0	—
Operating Income	-$163M	-$86M	-88.0%
Net Income	-$152M	-$86M	-77.1%